SELANK ® 0.15%

Dosage and Administration

One bottle of Selank contains 60 drops, each having 75 mcg of the active ingredient. The average dose is 2-3 drops in each nostril. Selank should be taken up to 3 times per day.

On-label regimen of Selank is 3 times a day, 2 drops in each nostril, for a period of 14 days. 

Side Effects

Irritation of the nasal mucosa and very rare allergic reactions.

Interaction With Other Drugs

Selank has no effect on depressants or stimulants including Haloperidol, Pentobarbital, Hexobarbital and analeptics. It can be combined with psychotherapy. It is safe to use with ethanol containing substances.


Selank was shown to be completely safe even when hundredfold doses were administered.


Keep in a dark place at a temperature less than 10°C (50°F) for up to two years.

Note: If there is a need to increase the effect of Selank, a second dose should be taken 15-minutes after the first one. 

Manufacture Contact Details:, Moscow, Russia


Selank® 0.15% is an anxiolytic peptide drug with nootropic properties. By its structure, Selank is based on endogenous tetrapeptide Tuftsin, which plays an important role in immune system. To slow the breakdown of peptide and prolong its effects, the inventors of Selank added a Glyproline to its structure.

Tafcin was found to have anxiolytic effects in 1995 and over the next decade Russian scientists were focusing on developing a peptide drug that was able to have the most pronounced anxiolytic effects. This research, as well as clinical trials lasted until 2009, when Selank was finally brought to market under the brand name Selank® 0.15%. It is produced on a GMP-compliant factory by Peptogen Inc

The spectrum of pharmacological action of the drug is unique. It is a popular over-the-counter anti-anxiety medicine with antidepressant and anti-asthenic actions; it also has a capacity to enhance memory and cognitive functions. 

The mechanism of anxiolytic action is related to the regulation of norepinephrine, serotonin and enkephalins levels and their metabolism in the brain. It is suggested that another possible mechanism of action is inhibition of enkephalin-degrading enzymes, which increases the activity of endogenous opioid system and explains the mild analgesic effect of Selank.

Numerous clinical trials confirmed the safety of this peptide, which was found to not form a dependence and to be non-toxic even in doses 200-500 times higher than therapeutic ones.

Primary Uses of Selank® 0.15%:

  • Anxiety and adjustment disorders;
  • Neurasthenia, emotional lability;
  • Stress-related disorders.

Is Selank going to be degraded after a long journey from Russia to the US?

  • In short, No. It is a pharmaceutical nootropic produced by Peptogen Inc. According to the official instruction (drug sheet), once opened a bottle of Selank® is to be kept at temperatures below 30°C (86°F) for a period of up to 30 days. Apart from that, we want to stress some other points:
  • The product contains methylparaben (0.01%), which works as a preservative and ensures longer shelf-life. It is considered safe and is frequently used in other drugs.
  • The product is sterile and is produced on a GMP-compliant factory, which is likely to increase storage duration.
  • For longer periods of time, Selank should be stored at temperatures below 10°C (50°F). The shelf life of a new product is 2 years if stored below 10°C (50°F).

This implies that if the temperature between 10°C (50°F) to 30°C (86°F) the storage duration is anywhere between 30 days to 2 years, depending on the temperature.


*Up until now, nobody complained about Selank being unusable due to the heat during transportation, though we have been shipping for more than three years by now.

  1. Zozulya et al (2001) The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
  2. Kost et al (2001) Semax and selank inhibit the enkephalin-degrading enzymes from human serum
  3. Sokolov et al (2002) Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions
  4. Kozlovskaya et al (2003) Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress
  5. I. Kozlovkii, N. Danchev (2003) The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats
  6. T. Ganshina, I. Kozlovskii (2005) Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats
  7. Semenova et al (2007) Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny
  8. Sarkisova et al (2008) Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice
  9. Zozulia et al (2008) Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
  10. Uchakina et al (2008) Immunomodulatory effects of selank in patients with anxiety-asthenic disorders
  11. Medvedev et al (2014) A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders
  12. Kolomin et al (2014) The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action
  13. Medvedev et al (2015) Optimization of the treatment of anxiety disorders with selank
  14. Volkova et al (2016) Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
  15. Kaisan et al (2017) Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
  16. Filatova et al (2017) GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
  17. Fomenko et al (2017) Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress
  18. Slominsky et al (2017) Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism